Journal
BMJ CASE REPORTS
Volume 14, Issue 2, Pages -Publisher
BMJ PUBLISHING GROUP
DOI: 10.1136/bcr-2021-241572
Keywords
COVID-19; contraindications and precautions; general guidance on prescribing; infections; drugs: respiratory system
Categories
Ask authors/readers for more resources
A 28-year-old man developed severe COVID-19 symptoms after taking the anabolic steroid oxandrolone for bodybuilding purposes. However, a marked improvement in symptoms and disease severity was observed after receiving a single dose of the novel antiandrogen proxalutamide, which is part of an experimental treatment for hyperandrogenic men with COVID-19. This case potentially links anabolic steroid use to COVID-19 disease severity.
A severe case of COVID-19 was observed in an otherwise healthy 28-year-old man who had taken oxandrolone 40mg/day as an anabolic steroid. The patient had been taking oxandrolone for enhanced bodybuilding 30 days prior to presenting to an outpatient clinic with COVID-19 symptoms. The patient reported that his symptoms have rapidly worsened over the course of 4days prior to presenting at the clinic. As part of an experimental antiandrogen treatment for hyperandrogenic men suffering from COVID-19, he was administered a single 600mg dose of the novel antiandrogen proxalutamide. Twenty-fourhours after administration of this dose, marked improvement of symptoms and markers of disease severity were observed. To our knowledge, this is the first case that potentially links anabolic steroid use to COVID-19 disease severity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available